Cervical Cancer Vaccine Could Cut Deaths By 75%
Posted on: Tuesday, 5 September 2006, 12:01 CDT
New research has suggested that GlaxoSmithKline's Cervarix vaccine could cut deaths from cervical cancer in the UK by more than 75%.
The GlaxoSmithKline-sponsored study found that deaths from cervical cancer would drop by 76% with 100% coverage. Cases of cancers in the vulva and vagina could also be reduced from the implementation of the vaccine.
The results were based on the theory that the vaccine would target 12-year-old girls, specifically before they became sexually active. However, they would still continue to receive cervical screenings throughout their life.
GlaxoSmithKline is competing with Merck & Co. which has manufactured a rival vaccine, Gardasil. Gardasil is set to receive a European license and already has received approval from the FDA. Cevarix is still being developed and therefore will not be sent for European approval until next year.
Source: Datamonitor
Related Articles
- FDA Advisory Committee Makes Favorable Recommendation for Cervarix, GlaxoSmithKline's Candidate Cervical Cancer Vaccine
- CDC Immunization Advisory Committee Recommends Two New Pediatric Vaccines From GlaxoSmithKline
- GlaxoSmithKline Receives FDA 'Complete Response' Letter for Cervical Cancer Vaccine
- Cervical-Cancer Vaccines' Makers Argue Over Study
- Glaxo vaccine reduces ear infection in toddlers
- Dynavax's HEPLISAV(TM) Hepatitis B Vaccine Shows Statistically Significant Efficacy In Phase 2/3 Clinical Trial
- Cervical Cancer Vaccine 'Available Within a Year'
- Vaccine 'in a Year' for Cervical Cancer
- GlaxoSmithKline Acquires Vaccine R&D and Manufacturing Plant in the US
- FDA Approves New Flu Vaccine From GlaxoSmithKline
 |
 |
User Comments (0)
RSS Feeds